PDF factsheet
      Z

All mechanism in diabetic kidney disease for all type of patients, clinical trials results

amlodipine versus placebo
IDNT (amlodipine vs PBO), 2001
Amlodipine 10 mg daily
versus
placebo
hypertensive patients with nephropathy due to type 2 diabetesdouble-blind
Follow-up duration: 2.6 years
Worldwide
fosinopril versus control
Fogari, 2002
amlodipine plus fosinopril (5/10 to 15/30 mg/day
versus
amlodipine (5 to 15 mg/day)
hypertensive patients with type 2 diabetes and microalbuminuria NA
Follow-up duration: NA
irbesartan versus amlodipine
IDNT (irbesartan vs amlodipine), 2001
Irbesartan 300 mg daily
versus
amlodipine 10 mg daily
hypertensive patients with nephropathy due to type 2 diabetes double blind
Follow-up duration: 2.6 years
Worldwide
irbesartan versus placebo
IDNT (irbesartan vs pbo), 2001
Irbesartan 300 mg daily
versus
placebo
hypertensive patients with nephropathy due to type 2 diabetes double blind
Follow-up duration: 2.6 years
Worldwide
IPDM (150mg), 2001
irbesartan 150 mg daily
versus
placebo
hypertensive patients with type 2 diabetes and microalbuminuriadouble-blind
Follow-up duration: 2 years
Worldwide
losartan versus placebo
RENAAL, 2001
losartan 50 to 100 mg once daily
versus
placebo
patients with type 2 diabetes and nephropathydouble-blind
Follow-up duration: 3.4 y
America, Europe, Asia
olmesartan versus placebo
ORIENT,
NCT00141453
olmesartan
versus
placebo
patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitusdouble-blind
Japan, Hong Kong
ramipril versus placebo
DIABHYCAR, 2004
ramipril 1.25 mg/day
versus
placebo
patients with type 2 diabetes who have microalbuminuria or proteinuriadouble-blind
Follow-up duration: median 4 years
Europe, North Africa
telmisartan versus enalapril
DETAIL, 2004
telmisartan 80 mg daily
versus
enalapril 20 mg daily
subjects with type 2 diabetes and early nephropathy double-blind
Follow-up duration: 5 year
temisartan versus enalapril
DETAIL, 2004
telmisartan 80 mg daily
versus
enalapril 20 mg daily
subjects with type 2 diabetes and early nephropathydouble-blind
Follow-up duration: 5 years
northern Europe

  Options


in first

in second

  Filter